An Assessment of Combination of the Camrelizumab With Chemotherapy in Metastatic Biliary Tract Cancers

BACKGROUND: Monoclonal antibodies that target the PD-1 receptor are emerging as promising therapeutic candidates for the treatment of biliary tract cancers (BTCs). The purpose of the current study was to assess the combination of the camrelizumab with chemotherapy as a first-line treatment for metas...

Descripción completa

Detalles Bibliográficos
Autores principales: Yu, Yi, Huang, Shanshan, Chen, Jun, Yu, Feng, Zhang, Lin, Xiang, Xiaojun, Deng, Jun, Fang, Ziling, Li, Junhe, Xiong, Jianping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8204626/
https://www.ncbi.nlm.nih.gov/pubmed/33982628
http://dx.doi.org/10.1177/10732748211017165

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8204626/
https://www.ncbi.nlm.nih.gov/pubmed/33982628
http://dx.doi.org/10.1177/10732748211017165

Ejemplares similares